(In thousands, except per-share amounts)

Company Symbol/ Revenues / Profits Per share R & D Cash 2 Shares Period % change Current/comp Current/comp % Change or Equiv.Celgene CELG/1Q 595/57% (2,674)/(2,281) (0.34)/(0.29) 2,158/21% 15,228 7,842DNA Plant Technology DNAP/1Q 4,028/139% (9,596)/(3,547) (0.39)/(0.20) 2,069/-14% 14,996 26,779Ecogen EECN/1Q 6,582/34% (346)/(2,546) (0.02)/(0.15) NA/NA 11,502 17,806Glycomed GLYC/3Q 689/97% (6,758)/(5,646) (0.54)/(0.46) 6,320/24% 81,361 12,631HemaCare HEMA/1Q 2,646/-21% (686)/(471) (0.14)/(0.11) 733/31% NA 4,792IBAH IBAH/1Q 49/0% (1,556)/(916) (0.29)/(0.17) NA/NA 4,040 5,408Immunex3 IMNX/1Q 39,533/NA (8,397)/NA (0.22)/NA 19,798/NA 20,600 38,790IMRE IMRE/1Q 1,080/-30% (1,283)/(1,323) (0.09)/(0.09) 428/-50% 505 15,073Interneuron Pharmaceuticals IPIC/2Q 81/-91% (6,286)/(3,740) (0.23)/(0.15) 3,931/3% 26,700 26,993Lidak Pharmaceuticals LDAKA/2Q 239/50% (1,082)/(810) (0.05)/(0.05) NA/NA 9,763 23,745Medarex MEDX/1Q 106/-11% (1,891)/(928) (0.30)/(0.15) NA/NA 6,975 6,372MicroProbe MPRO/1Q 323/6% (4,011)/(2,129) (0.58)/(0.59) 2,199/97% 6,148 6,947Neurex NXCO/2Q 423/1% (2,358)/(1,508) (0.23)/(1.43) 2,260/52% 14,261 9,943Procept PRCT/1Q 1,517/229% (1,618)/(1,949) (0.46)/(0.50) 2,263/30% 20,254 3,552Seragen SRGN/1Q 8/NA1 (4,853)/(5,219) (0.37)/(0.35) 3,871/-2% 12,381 12,702SyStemix STMX/1Q 1,680/20% (7,400)/(2,720) (0.76)/(0.20) 7,812/88% 33,286 9,755Texas Biotechnology TXB.E/1Q 251/239% (2,400)/(1,778) (0.19)/(0.21) 1,732/35% 24,743 13,010Zonagen ZONA/1Q 40/NA1 (819)/(442) (0.22)/(0.23) 573/127% 5,303 3,694

1. Zero revenue in comparable quarter in 19932. Includes cash, cash equivalents, short-term investments andmarketable securities3. Results not comparable to 1Q of 1993 because Immunex mergedwith Lederle Oncology Corp. on June 1, 1993

All NASDAQ except Texas Biotechnology (AMEX)

ClarificationCytoTherapeutics Inc. of Providence, R.I., had cash and cashequivalents of about $25.4 million for the quarter ending on March 31.

(c) 1997 American Health Consultants. All rights reserved.